What’s Next for Madrigal Pharmaceuticals Inc (MDGL) After Today’s Huge Increase?

September 17, 2017 - By Ellis Scott

The stock of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) is a huge mover today! The stock increased 3.69% or $0.67 on September 15, reaching $18.81. About 113,960 shares traded or 276.30% up from the average. Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.
The move comes after 7 months positive chart setup for the $235.04M company. It was reported on Sep, 17 by Barchart.com. We have $19.37 PT which if reached, will make NASDAQ:MDGL worth $7.05M more.

More notable recent Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) news were published by: Globenewswire.com which released: “Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results” on May 11, 2017, also Globenewswire.com with their article: “Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License …” published on September 19, 2016, Globenewswire.com published: “Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL …” on February 23, 2017. More interesting news about Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) were released by: Seekingalpha.com and their article: “Synta – Madrigal Merger: Is There A Potential Value Play Here?” published on August 23, 2016 as well as Globenewswire.com‘s news article titled: “Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL …” with publication date: October 20, 2016.

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The company has market cap of $235.04 million. The Firm focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis . It currently has negative earnings. The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.